Advanced search
Publication Cover
Scandinavian Journal of Urology Volume 54, 2020 - Issue 6
Journal homepage
240
Views
10
CrossRef citations to date
0
Altmetric
Articles

Too good for CARMENA: criteria associated with long systemic therapy free intervals post cytoreductive nephrectomy for metastatic clear cell renal cell carcinoma

Eduard Roussela Department of Urology, University Hospitals Leuven, Leuven, BelgiumView further author information
,
Annelies Verbiestb Department of Medical Oncology, University Hospitals Leuven, Leuven, BelgiumView further author information
,
Uros Milenkovica Department of Urology, University Hospitals Leuven, Leuven, BelgiumView further author information
,
Ben Van Cleynenbreugela Department of Urology, University Hospitals Leuven, Leuven, BelgiumView further author information
,
Hendrik Van Poppela Department of Urology, University Hospitals Leuven, Leuven, BelgiumView further author information
,
Steven Joniaua Department of Urology, University Hospitals Leuven, Leuven, BelgiumView further author information
,
Benoit Beuselinckb Department of Medical Oncology, University Hospitals Leuven, Leuven, BelgiumView further author information
&
Maarten Albersena Department of Urology, University Hospitals Leuven, Leuven, BelgiumCorrespondence[email protected]
View further author information
 show all
Pages 493-499 | Received 02 Jun 2020, Accepted 20 Aug 2020, Published online: 14 Sep 2020

References

  • Hsieh JJ, Purdue MP, Signoretti S, et al. Renal cell carcinoma. Nat Rev Dis Primers. 2017;3:17009.
  • Capitanio U, Bensalah K, Bex A, et al. Epidemiology of renal cell carcinoma. Eur Urol. 2019;75(1):74–84.
  • Flanigan RC, Salmon SE, Blumenstein BA, et al. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med. 2001;345(23):1655–1659.
  • Mickisch GHJ, Garin A, Van Poppel H, et al. Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet. 2001;358(9286):966–970.
  • Tsao C. k, Small AC, Kates M, et al. Cytoreductive nephrectomy for metastatic renal cell carcinoma in the era of targeted therapy in the United States: a SEER analysis. World J Urol. 2013;31(6):1535–1539.
  • Motzer RJ, Tannir NM, McDermott DF, et al. Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. N Engl J Med. 2018;378(14):1277–1290.
  • Motzer RJ, Powles T, Atkins MB, et al. IMmotion151: a randomized phase III study of atezolizumab plus bevacizumab vs sunitinib in untreated metastatic renal cell carcinoma (mRCC). J Cin Oncol. 2018;36(6_suppl):578–578.
  • Rini BI, Plimack ER, Stus V, et al. Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med. 2019;380(12):1116–1127.
  • Hanna N, Sun M, Meyer CP, et al. Survival analyses of patients with metastatic renal cancer treated with targeted therapy with or without cytoreductive nephrectomy: a national cancer data base study. J Cin Oncol. 2016;34(27):3267–3275.
  • Bhindi B, Abel EJ, Albiges L, et al. Systematic review of the role of cytoreductive nephrectomy in the targeted therapy era and beyond: an individualized approach to metastatic renal cell carcinoma. Eur Urol. 2019;75(1):111–128.
  • Heng DYC, Wells JC, Rini BI, et al. Cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium. Eur Urol. 2014;66(4):704–710.
  • Méjean A, Ravaud A, Thezenas S, et al. Sunitinib alone or after nephrectomy in metastatic renal-cell carcinoma. N Engl J Med. 2018;379(5):417–427.
  • Kushnir I, Basappa NS, Ghosh S, et al. Active surveillance in metastatic renal cell carcinoma (mRCC): results from the Canadian Kidney Cancer information system (CKCis). J Cin Oncol. 2019;37(15_suppl):4516–4516.
  • Ruatta F, Derosa L, Albiges L, et al. Prognosis of renal cell carcinoma with bone metastases: experience in 300 consecutive patients. J Cin Oncol. 2017;35(6_suppl):463–463.
  • Kalogirou C, Mulfinger P, Sokolakis I, et al. Preoperative C-reactive protein values as a potential component in outcome prediction models of metastasized renal cell carcinoma patients receiving cytoreductive nephrectomy. Urol Int. 2017;99(3):297–307.
  • Culp SH, Tannir NM, Abel EJ, et al. Can we better select patients with metastatic renal cell carcinoma for cytoreductive nephrectomy? Cancer. 2010;116(14):3378–3388.
  • Beuselinck B, Oudard S, Rixe O, et al. Negative impact of bone metastasis on outcome in clear-cell renal cell carcinoma treated with sunitinib. Ann Oncol. 2011;22(4):794–800.
  • Beuselinck B, Vano Y-A, Oudard S, et al. Prognostic impact of baseline serum C-reactive protein in patients with metastatic renal cell carcinoma (RCC) treated with sunitinib. BJU Int. 2014;114(1):81–89.
  • Guckenberger M, Lievens Y, Bouma AB, et al. Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation. Lancet Oncol. 2020;21(1):e18–e28.
  • Verbiest A, Renders I, Caruso S, et al. Clear-cell renal cell carcinoma: molecular characterization of IMDC risk groups and sarcomatoid tumors. Clin Genitourin Cancer. 2019;17(5):e981–e994.
  • Kuusk T, Szabados B, Liu WK, et al. Cytoreductive nephrectomy in the current treatment algorithm. Ther Adv Med Oncol. 2019;11:1758835919879026.
  • Larcher A, Wallis CJD, Bex A, et al. Individualised indications for cytoreductive nephrectomy: which criteria define the optimal candidates? Eur Urol Oncol. 2019;2(4):365–378.
  • Motzer RJ, Mazumdar M, Bacik J, et al. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Cin Oncol. 1999;17(8):2530–2530.
  • Bex A, Mulders P, Jewett M, et al. Comparison of immediate vs deferred cytoreductive nephrectomy in patients with synchronous metastatic renal cell carcinoma receiving sunitinib: the SURTIME randomized clinical trial. JAMA Oncol. 2019;5(2):164–170.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.